Nanotechnology financiers were biting their nails this past October as market forces were engaged by regulatory forces.
Intangible Asset Finance: Investing in Effectiveness
Nanotechnology financiers were biting their nails this past October as market forces were engaged by regulatory forces. In the same week, the U.S. Food and Drug Administration ('FDA') held its first full public meeting on nanotechnology safety and environmental risk, and the Environmental Protection Agency ('EPA') placed a Notice of Rulemaking regarding nanotech product commercial release requirements in the Congressional Record. Investors see only risk — each of the two agencies has the power to shut down the evolving nanotechnology industry.
By
Nir Kossovsky And Robert BlockThis premium content is locked for LawJournalNewsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN LawJournalNewsletters
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already have an account? Sign In Now
For enterprise-wide or corporate access, please contact Customer Service at [email protected] or call 1-877-256-2473.
